A Phase 1 interventional study of Empagliflozin and Metformin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-27.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of two strength of empagliflozin and metformin (Part I) under fasted and under fed conditions and bioequivalence of empagliflozin/metformin (FDC) tablet compared with single tablets empagliflozin and metformin under fed conditions (Part II).
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Drug: Empagliflozin/Metformin
fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Drug: Empagliflozin/Metformin
tablets, oral with 240 ml water under fasted conditions
Drug: Empagliflozin · Drug: Metformin
tablets, oral with 240 ml water under fed conditions
Drug: Empagliflozin · Drug: Metformin
fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Drug: Empagliflozin/Metformin
tablets, oral with 240 ml water under fed conditions
Drug: Empagliflozin · Drug: Metformin
medium dose oral administration
oral administration
low dose of Empagliflozin oral administration
Drug pages: Empagliflozin · Metformin
low dose of Empagliflozin
oral administration
Drug pages: Empagliflozin · Metformin
medium dose of Empagliflozin oral administration
medium dose oral administration
oral administration
Drug pages: Empagliflozin · Metformin
medium dose of Empagliflozin oral administration
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin
AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Empagliflozin
Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin
AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Metformin
Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin
Cmax: maximum measured concentration of the analyte in plasma for Empagliflozin
Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Maximum Measured Concentration of the Analyte in Plasma, Metformin
Cmax: maximum measured concentration of the analyte in plasma for Metformin
Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin
AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Empagliflozin
Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin
AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Metformin
Time frame: 1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
| Milestone | Emp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met Fed | Emp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met Fasted | Emp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met Fed | Emp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met Fasted | Low Dose Emp: Emp/Met / Emp+Met | Low Dose Emp: Emp+Met / Emp/Met |
|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 12 | 12 |
| Completed | 6 | 6 | 6 | 5 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 |
AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Empagliflozin
| nmol*h/L | 1 Empagliflozin/Metformin (T) | 2 Empagliflozin/Metformin (T) | 3 Empagliflozin + Metformin (R) | 4 Empagliflozin + Metformin (R) | 5 Empagliflozin/Metformin (T) | 6 Empagliflozin + Metformin (R) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin | 2810 ± 19.3 | 2580 ± 20.4 | 2760 ± 20.0 | 2570 ± 20.7 | 988 ± 16.2 | 927 ± 18.0 |
AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Metformin
| ng*h/mL | 1 Empagliflozin/Metformin (T) | 2 Empagliflozin/Metformin (T) | 3 Empagliflozin + Metformin (R) | 4 Empagliflozin + Metformin (R) | 5 Empagliflozin/Metformin (T) | 6 Empagliflozin + Metformin (R) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin | 10400 ± 23.0 | 9220 ± 26.4 | 11000 ± 26.8 | 9140 ± 22.9 | 9080 ± 32.7 | 9060 ± 26.7 |
AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Empagliflozin
| nmol*h/L | 1 Empagliflozin/Metformin (T) | 2 Empagliflozin/Metformin (T) | 3 Empagliflozin + Metformin (R) | 4 Empagliflozin + Metformin (R) | 5 Empagliflozin/Metformin (T) | 6 Empagliflozin + Metformin (R) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin | 2770 ± 19.2 | 2530 ± 20.1 | 2720 ± 20.0 | 2510 ± 20.2 | 962 ± 16.3 | 903 ± 18.2 |
Cmax: maximum measured concentration of the analyte in plasma for Empagliflozin
| nmol/L | 1 Empagliflozin/Metformin (T) | 2 Empagliflozin/Metformin (T) | 3 Empagliflozin + Metformin (R) | 4 Empagliflozin + Metformin (R) | 5 Empagliflozin/Metformin (T) | 6 Empagliflozin + Metformin (R) |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin | 379 ± 23.7 | 276 ± 24.8 | 375 ± 27.3 | 258 ± 28.5 | 108 ± 16.9 | 103 ± 14.5 |
Cmax: maximum measured concentration of the analyte in plasma for Metformin
| ng/mL | 1 Empagliflozin/Metformin (T) | 2 Empagliflozin/Metformin (T) | 3 Empagliflozin + Metformin (R) | 4 Empagliflozin + Metformin (R) | 5 Empagliflozin/Metformin (T) | 6 Empagliflozin + Metformin (R) |
|---|---|---|---|---|---|---|
| Maximum Measured Concentration of the Analyte in Plasma, Metformin | 1580 ± 26.9 | 1160 ± 17.8 | 1680 ± 25.8 | 1180 ± 21.2 | 1180 ± 23.8 | 1150 ± 24.8 |
AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Metformin
| ng*h/mL | 1 Empagliflozin/Metformin (T) | 2 Empagliflozin/Metformin (T) | 3 Empagliflozin + Metformin (R) | 4 Empagliflozin + Metformin (R) | 5 Empagliflozin/Metformin (T) | 6 Empagliflozin + Metformin (R) |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin | 10100 ± 21.3 | 8960 ± 24.5 | 10700 ± 24.1 | 8930 ± 22.5 | 8870 ± 30.8 | 8850 ± 26.3 |
Collected over From first trial medication intake until next intake or the end-of-trial visit, 10 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 Empagliflozin/Metformin (T) | — | 0/23 (0%) | 6/23 (26.1%) |
| 2 Empagliflozin/Metformin (T) | — | 0/24 (0%) | 6/24 (25%) |
| 3 Empagliflozin + Metformin (R) | — | 0/24 (0%) | 4/24 (16.7%) |
| 4 Empagliflozin + Metformin (R) | — | 0/24 (0%) | 6/24 (25%) |
| 5 Empagliflozin/Metformin (T) | — | 0/23 (0%) | 9/23 (39.1%) |
| 6 Empagliflozin + Metformin (R) | — | 0/23 (0%) | 10/23 (43.5%) |
| Event | 1 Empagliflozin/Metformin (T) | 2 Empagliflozin/Metformin (T) | 3 Empagliflozin + Metformin (R) | 4 Empagliflozin + Metformin (R) | 5 Empagliflozin/Metformin (T) | 6 Empagliflozin + Metformin (R) |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/23 | 3/24 | 1/24 | 4/24 | 4/23 | 6/23 |
| HeadacheNervous system disorders | 4/23 | 0/24 | 2/24 | 1/24 | 3/23 | 4/23 |
| NauseaGastrointestinal disorders | 1/23 | 0/24 | 1/24 | 0/24 | 3/23 | 1/23 |
| VomitingGastrointestinal disorders | 1/23 | 1/24 | 0/24 | 1/24 | 2/23 | 0/23 |
| NasopharyngitisInfections and infestations | 1/23 | 2/24 | 0/24 | 1/24 | 0/23 | 0/23 |
Treated Set (TS): includes all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment
| Age, Continuous(years) | Emp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met Fed | Emp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met Fasted | Emp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met Fed | Emp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met Fasted | Low Dose Emp: Emp/Met / Emp+Met | Low Dose Emp: Emp+Met / Emp/Met | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33.5 ± 6.7 | 26.5 ± 9.7 | 28.5 ± 9.5 | 33.2 ± 7.1 | 32.8 ± 9.8 | 32.3 ± 9.6 | 31.5 ± 8.9 |
| Sex: Female, Male(Participants) | Emp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met Fed | Emp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met Fasted | Emp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met Fed | Emp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met Fasted | Low Dose Emp: Emp/Met / Emp+Met | Low Dose Emp: Emp+Met / Emp/Met | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 1 | 4 | 7 | 7 | 25 |
| Male | 3 | 3 | 5 | 2 | 5 | 5 | 23 |
The record gives a start of Mar 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Metformin